一张丙肝入场券!东阳光药如何从肝病赛道突围

医药研究社
Sep 26

东阳光药如何从肝病赛道突围?来源|医药研究社吉利德科学的丙肝药物帝国正在收缩,明星产品丙通沙在2025年第一季度仅实现3.46亿美元营收,远低于其丙肝系列药物曾创下的191亿美元年销售额峰值。“丙肝领域可做的事情已经不多了。”——2018年吉利德CEO的断言,似乎已成为现实,至少在全球主要成熟市场如此。然而,这一看似饱和的市场,在中国却可能是故事的开始。东阳光药正以空前的投入,组建百人级肝病专线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10